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Abstract: The effect of omega-3 (n-3) in asthma has been inconclusive. One explanation for it may be the low 
incorporation of these fatty acids in clinical studies. Phosphoethanolamine (PEtn) can increase the synthesis of 
phosphatidylethanolamine, which can, in turn, increase the incorporation of n-3 in cell membranes. The aim of this 
study is to evaluate the effect of synthetic PEtn in patients with asthma who are receiving n-3. This randomized, 
double-blind, placebo-controlled study was carried out over a two month period by using spirometry, the Asthma 
Control Test questionnaire (ACT) and medicine intake. Forty-one patients with asthma were studied. Twenty-one pa-
tients received n-3 daily (1.080 mg of EPA, 720 mg of DHA) and 800 mg of PEtn (PEtn group), and twenty patients 
received the same doses of n-3 and placebo (control group). All patients continued receiving their conventional 
treatment for asthma. The hospital ethics committee approved the study. Five patients of each group required sys-
temic corticosteroids, being the total consumption, smaller in the PEtn group (127.4 mg of prednisone/patient ver-
sus 416.0 mg of prednisone/patient in the control group, p-value = 0.0269). There were no significant differences 
in the changing of ATC and FEV1, as well as in the intake of formoterol or budesonide between the groups. In this 
study, patients who received phosphoethanolamine and omega-3 needed a smaller dose of systemic corticosteroid 
for asthma control than patients who only received omega-3. However, as the trial was conducted on a small scale, 
more studies are necessary.
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Introduction
Although epidemiological and experimental 
studies have demonstrated an anti-inflamma-
tory effect of omega-3 (n-3), clinical studies in 
asthma have presented inconsistent results. 
One of the possible explanations for these dis-
cordant findings may be the low incorporation 
of n-3 into the cell membrane in clinical stud-
ies, because in clinical studies, the doses of 
n-3 are shorter or smaller than in epidemiologi-
cal and experimental studies [1-14]. 
Omega-3 is incorporated into cell membranes 
by phospholipids. Among phospholipids, phos-
phatidylethanolamine (PtdEtn) exerts a funda-
mental role in the n-3 incorporation, because, 
besides having n-3 in its molecule, PtdEtn is 
the substrate for the synthesis of other phos-
pholipids with long polyunsaturated fatty acids, 
such as phosphatidylcholine (PtdCho) with 
long-polyunsatureted fatty acid. While arachi-
donic acid (AA) is predominantly incorporated in 
PtdCho, long-chain n-3 is predominantly incor-
porated in PtdEtn, mostly 22:6 docosahexae-
noic acid (DHA). In the FtdEth synthesis, there is 
selectivity for DHA, and it has been attributed 
to the specificity of the enzyme that binds the 
phosphoethanolamine (PEtn) to the diacylglyc-
erol. This enzyme, CDP-ethanolamine: 1,2-diac-
ylglycerolethanolamine-phosphotransferase, 
shows a specificity for 16:0-22:6-diacylglycerol 
[15-20]. 
It is important to be highlighted that the synthe-
sis of FtdEtn has a limiting step, that is, the 
phosphorylation of ethanolamine to form PEtn, 
which is the phosphate radical of this phospho-
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lipid. This limiting step of FtdEtn synthesis may 
be overcome by the supplying of ready-made 
PEtn [21, 22].
As the providing of ready-made PEtn can, theo-
retically, improve the synthesis of FtdEtn, and 
as this phospholipid synthesis is selective for 
n-3, mainly DHA, our hypothesis is that provid-
ing synthetic PEtn and n-3, it is possible to 
improve the incorporation of n-3 in cell mem-
branes, improving inflammatory processes 
such as asthma. This study aimed to evaluate 
the clinical effects of PEtn in patients with asth-
ma who are being supplemented with n-3. 
Method
Study oversight
Study Design was conducted at School of 
Medical Sciences, of the State University of 
Campinas. The protocol of the study was 
approved by the human ethics committees 
of the State University of Campinas (IRB 
00002737), and all participants gave written 
informed consent. The study was conducted in 
accordance with the International Conference 
on Harmonization guidelines for Good Clinical 
Practice and the principles of the Declaration 
of Helsinki.
The capsules of synthetic PEtn 400 mg (2-ami-
noethyl dihydrogen phosphate, in solid form, 
with calcium, magnesium and zinc) were pro-
duced by the Institute of Chemistry, University 
of São Paulo, São Carlos, Brazil. These cap-
sules were donated to study, as well as the 
omega-3,500 mg capsules.
All the authors were involved in each stage of 
the manuscript development, made the deci-
sion to submit the manuscript for publication, 
and take responsibility for the accuracy and 
completeness of the data and analyses.
Patients
This study was composed of asthmatic patients 
assisted at Hospital das Clinicas of State 
University of Campinas, in the city of Campinas, 
Brazil. Eligible participants were 18 years of 
age or older, who had not received systemic 
corticosteroid and who had not the dose of 
inhaled corticosteroid changed during the four 
weeks before the beginning of the study. 
Study procedures
A total of 41 eligible patients was randomly 
assigned in a 1:1:1 ratio to receive either 12 
omega-3 500 mg capsules (equivalent to 1.080 
mg of eicosapentaenoic acid-EPA, 720 mg of 
DHA) plus two synthetic PEtn 400 mg capsules 
per day (PEtn group), or to receive the same 
dose of omega-3 plus two amide capsules per 
day (control group). Patients and clinicians were 
blind to treatment allocation. These treatments 
lasted two months, and all patients continued 
to receive conventional treatment prescribed 
by physicians of the ambulatory department.
Monthly visits were performed. Consumption of 
medicines for asthma treatment was regis-
tered. The questionnaire on quality of life 
“Asthma Control Test” (ACT), with the Brazilian 
Portuguese version, was carried [23, 24]. 
Spirometries were performed before and after 
treatment, according to American Thoracic 
Society criteria [25]. It was used the Master- 
Scope spirometer, Jaeger, by Viasys Healthcare 
(Germany).
Table 1. Baseline Characteristics of the Patients
 Total (N = 41) PEtn Group (N = 21) Control Group (N = 20)
Age (y)-mean (SD) 48.5 (11.1) 48.6 (9.7) 48.5 (12.4)
Female sex-n (%) 33 (80.4) 18 (85.7) 15 (75.0)
Smoking-n 0 0 0
Atopic symptoms-n (%) 31 (75.6) 16 (71.1) 15 (75)
ACT-mean (SD) 15.4 (4.5) 15.6 (4.4) 15.2 (4.8)
FEV1 (l)-mean (SD) 1.79 (0.60) 1.78 (0.73) 1.81 (0.43)
% Predicted-mean (SD) 68.5 (17.6) 68.9 (19.9) 68.1 (15.4)
Formoterol dose (mcg/day)-mean (SD) 20.6 (9.8) 21.4 (8.6) 19.8 (11.1)
Budesonide dose (mcg/day)-mean (SD) 829.2 (353.7) 761.9 (352.2) 900.0 (364.1)
Definition of abbreviations: ATC = Asthma Control Test; FEV1 = forced expiratory volume in the first second.
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Study outcomes
The primary study outcome was the changing in 
spirometric values. Secondary outcomes were 
changing in ACT, changing in the consumption 
of medicine for asthma treatment and adverse 
effects of the treatment.
Statistical analysis
Linear mixed models were fitted to the data, 
including the effects of group (PEtn and con-
trol), time point, and a random effect by patient, 
as the two observations of the same patient 
are correlated. The following response vari-
ables were analyzed: ACT score, forced expira-
tory volume in the first second (FEV1), formoter-
ol and budesonide intake. An analysis of vari-
ance model was also fitted to the total of pred-
nisone taken by patients who needed systemic 
corticosteroids during the study [26-28].
Results
Forty-one patients were included. The data of 
the groups of patients are shown in Table 1. 
Patients from the PEtn group presented a larg-
er increase in FEV1 during the study (from 
1.79±0.74 liters to 1.94±0.84 liters versus 
from 1.81±0.43 liters to 1.86±0.55 liters in 
control group), but the difference between the 
groups was not statistically significant (P = 
0.1628).
Patients from the PEtn group presented a larg-
er increase in FEV1 during the study (from 
nide, as prescribed by their physicians. The 
consumption of these medicines did not pres-
ent statistically significant differences during 
the study, neither for formoterol (P = 0.5297) 
nor budesonide (P = 0.2961. Table 2).
Ten patients needed systemic corticosteroid 
for controlling asthma, five patients in each 
group. In this subgroup of patients, the con-
sumption of systemic corticosteroid was sig- 
nificantly smaller in PEtn subgroup (127.40± 
42.82 mg of prednisone/patient versus 
416.00±234.79 mg of prednisone/patient in 
control subgroup (P = 0.0269. Table 3).
The prevalent side effect was gastric intoler-
ance: four patients of each group, being one 
patient had improvement of stomachache af- 
ter stopping alendronate intake. Two patients 
of each group had weight alteration. Three 
patients in the placebo group had, respectively, 
headache, pneumonia, and hair loss (Table 4).
Discussion
One possible explanation for disappointing 
results in clinical studies with n-3 in asthma 
may be the low incorporation of n-3 into the cell 
membrane. Our hypothesis is that providing 
PEtn together n-3 might, it could be expected 
an improvement in n-3 incorporation, with a 
consequent improvement in the inflammatory 
process of asthma.
Our outcomes showed a significant effect only 
in a subgroup of patients, those need systemic 
Table 2. Variation of ATC, FEV1 and inhaled medications in PEtn 
and Control groups
FEtn Group Control Group
ATC-D0, mean (SD) 15.6 (4.4) 15.25 (4.8)
ATC-D60, mean (SD) 20.7 (3.9) 17.8 (6.1)
FEV1 (l)-D0, mean (SD) 1.78 (0.73) 1.81±0.43
% Predicted-mean (SD) 68.9 (19.9) 68.1 (15.4)
FEV1 (l)-D60, mean (SD) 1.94±0.83 1.86±0.55
% Predicted-mean (SD) 74.0 (20.7) 69.7 (15.3)
Formoterol (mcg/day)-D0, mean (SD) 21.4 (8.6) 19.8 (11.1)
Formoterol (mcg/day)-D60, mean (SD) 23.7 (4.8) 19.8 (8.9)
Budesonide (mcg/day)-D0, mean (SD) 761.9 (352.2) 900.0 (364.1)
Budesonide (mcg/day)-D60, mean (SD) 819.0 (244.1) 820.0 (303.6)
Definition of abbreviations: ATC-D0 = Asthma Control Test at beginning of the 
study; ATC-D60 = Asthma Control Test at the end of the study; FEV1-D0 = forced 
expiratory volume in the first second, at beginning of the study; FEV1-D60 = 
forced expiratory volume in the first second, at the end of the study. 
1.79±0.74 liters to 1.94±0.84 
liters versus from 1.81±0.43 
liters to 1.86±0.55 liters in con-
trol group), but the difference 
between the groups was not sta-
tistically significant (P = 0.1628. 
Table 2). 
ACT score presented an increase 
in both groups, being bigger in 
the PEtn group (from 15.62± 
4.43 to 20.71±3.99 versus from 
15.25±4.85 to 17.85±6.17 in 
the control group), but the differ-
ence was not statistically signifi-
cant between the groups (P = 
0.2068. Table 2).
All patients continued using in- 
haled formoterol and budeso- 
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corticosteroids for the asthma control. This 
subgroup probably consists of more severe 
patients. The effect seen in this subgroup is 
due to two hypotheses: the symptoms of asth-
ma are intense and variable in this subgroup, 
affecting more the systemic corticosteroids 
prescription. Another hypothesis is the treat-
ment, in fact, might have a visible effect only in 
more severe asthma. This finding suggests the 
subgroup that received n-3 and PEtn might 
have a less intensive inflammation in the air-
ways than subgroup that received only n-3 and 
placebo.
There are some limitations in this study such as 
the small number of patients and the lack of a 
more precise methodology to assess the asth-
ma inflammation. This study could be improved 
with the measurement of specific inflammatory 
biomarkers for asthma [29]. Furthermore, n-3 
incorporation was not studied. This incorpora-
tion could be evaluated by specific methods, 
such as the measurement of plasmatic EPA 
and DHA for acute changes in intake, and the 
measurement of platelet and mononuclear cell 
EPA and DHA, which relate to long-term intake 
of n-3 [30]. 
In conclusion, in this study, patients who 
received phosphoethanolamine and omega-3 
needed a smaller dose of systemic corticoste-
roid for asthma control than patients who only 
received omega-3. However, as the trial was 
conducted on a small scale, more studies are 
necessary to consider this combination as a 
possible modality of asthma treatment.
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Table 3. Characteristics of patients who need systemic corticosteroids during the study
Total PEtn Subgroup Control Subgroup
Total No. 10 5 5
Age (y), mean (SD) 46.8 (10.3) 48.6 (12.2) 45 (9.0)
Male: female (% male) 2:8 (20) 5:0 (0) 2:3 (25)
Smoking, n 0 0 0
Atopic symptoms, n (%) 8 (80) 4 (80) 4 (80)
ACT-D0, mean (SD) 14.5 (5.7) 14.8 (4.4) 14.2 (7.2)
ACT-D60, mean (SD) 16.2 (6.6) 18.4 (4.8) 14.0 (7.9)
FEV1-DO, (l), mean (SD) 1.68 (0.47) 1.43 (0.53) 1.92 (0.23)
% Predicted, mean (SD) 65.2 (21.9) 62.5 (26.8) 67.9 (18.5)
FEV1-D60, (l), mean (SD) 1.69 0.60) 1.50 (0.27) 1.89 (0.80)
% Predicted, mean (SD) 64.5 (18.7) 65.9 (21.2) 63.2 (18.3)
Formoterol (mcg/day)-D0, mean (SD) 21.0 (11.7) 20.4 (11.6) 21.6 (13.1)
Formoterol (mcg/day)-D60, mean (SD) 28.2 (8.0) 25.2 (2.6) 31.2 (10.7)
Budesonide (mcg/day)-D0, mean (SD) 740 (377) 680 (268) 680 (268)
Budesonide (mcg/day)-D60, mean (SD) 860 (353) 800 (489) 1.040 (357)
Total dose of prednisone (mg/patient), mean (SD) 272.7 (221.3) 127.4 (42.8) 416.0 (234.7)
Definition of abbreviations: ATC-D0 = Asthma Control Test at beginning of the study; ATC-D60 = Asthma Control Test at the end 
of the study; FEV1-D0 = forced expiratory volume in the first second, at beginning of the study; FEV1-D60 = forced expiratory 
volume in the first second, at the end of the study. 





Stomachache, n (%) 1 (4.7) 1 (5)
Heartburn, n (%) 1 (4.7) 1 (5)
Náusea, n (%) 2 (9.5) 2 (10)
Constipation, n (%) 0 1 (5)
Diarrhea, n (%) 0 1 (5)
Weight loss, n (%) 2 (9.5) 1 (5)
Weight gain, n (%) 0 1 (5)
Headache, n (%) 0 1 (5)
Pneumonia, n (%) 0 1 (5)
Hair loss, n (%) 0 1 (5)
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